Skip to content
Still Well After 40
Menu

Peptides After 40: Why Nobody's Paying to Find Out

Is BPC-157 legal now? What the new HHS policy does and doesn't make legal for BPC-157, TB-500 and four others, why the evidence is still thin, and why nobody is testing your vial.

By Adam Greene · · Updated · 12 min read

Rows of small unlabeled glass vials with silver crimp caps in a round laboratory tray
Photo: Jess Loiterton / Pexels (model; not an endorsement)

I’m 50, I’m on TRT under a doctor’s care, and I’m not a physician. That’s the only disclaimer you’re getting.

If you spend any time in gyms, podcasts or men’s health forums, you’ve heard about peptides. BPC-157 for the shoulder that clicks. CJC-1295 and ipamorelin for “natural” growth hormone. GHK-Cu for your skin. Semaglutide and tirzepatide for the weight.

Some people call them miracle molecules. Others call them expensive urine with a forum thread attached. Both camps are being lazy. It’s messier than either one says, and most of the mess comes down to who pays for research.

My interest in peptides started with my own shoulder. A physician prescribed a compounded blend of BPC-157 and TB-500, sold under the nickname “Wolverine stack,” for an injury that had bothered me for more than two years. It came from a compounding pharmacy under the label of a well-known men’s health company. My results were impressive. At the time I didn’t know what compounding meant, that neither peptide is FDA-approved, or what the risks might be. I trusted that doctor and the brand name.

That experience sent me reading everything I could find, and I quickly learned how thin the human evidence is. Most of what exists for BPC-157 and TB-500 comes from animal studies, with very few controlled human trials, and almost nothing on taking the two together. Compounded products also aren’t reviewed by the FDA for safety, effectiveness or quality the way approved drugs are.

That gap is why I started the Open Peptide Project, a nonprofit in formation. Our long-term goal is to support well-designed, patient-led clinical studies that produce real data on who peptides help, who they don’t, and what the risks are. One person’s results, including mine, don’t prove anything on their own. Good studies do.

This week the legal side got a lot of headlines, and some of them are wrong. So I’ve updated this piece. The legal section is rebuilt from the government’s own documents. The rest of my argument hasn’t changed, because the evidence hasn’t.

There are two peptide worlds, and the wall between them is money

This is the most important thing in the article, so it goes first.

World one: patented, FDA-approved peptides. Semaglutide, tirzepatide, a handful of others. Large randomized human trials. Inspected factories. A pharmacy and a prescription.

World two: everything else. BPC-157, TB-500, CJC-1295, ipamorelin, GHK-Cu, and a rotating cast of cousins. Sold online labeled “for research use only, not for human consumption.” That label is a legal fig leaf that lets a seller ship you a vial the FDA has never approved for anyone.

That fig leaf is getting thinner. In August 2026, FDA sent warning letters to five online peptide sellers saying a “research use only” label doesn’t count when the same site sells the mixing water to inject it (example letter). None of those five letters named BPC-157, but the logic applies to every vial in world two.

And now HHS has said the quiet part in writing. Its new policy says it’s meant to “discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers” (HHS policy). World two didn’t get legalized. HHS opened a side door into world one for six of these peptides, under conditions, through a pharmacy.

Most of the gym-famous peptides still live in world two. What keeps them there is mostly money.

Why the evidence is thin, and who benefits from that

A pivotal trial, the big one the FDA approves a drug on, runs a median of about $19 million, and the expensive ones run past $100 million (JAMA Internal Medicine, 2018). Add years of earlier work before you even get there. You only spend that money if you can own the thing afterward.

Now look at what BPC-157 actually is: a short fragment of a protein found in human stomach juice, described back in the early ’90s (Sikirić et al., J Physiol Paris, 1993). You can’t patent a natural fragment very well. You can patent a formulation or a specific use, but you don’t get the fortress Novo Nordisk has around semaglutide. That fortress is why they can charge what they charge and fund trial after trial.

So the logic runs like this:

A cheap, off-patent peptide shows promise in animals.

Nobody owns it, so nobody funds the trial.

The FDA looks at the file, sees no Phase III, and writes “insufficient evidence.”

The wellness industry quotes the FDA saying “insufficient evidence.”

Everybody concludes the molecule is probably junk.

Step three is true. But a lot of the time, “insufficient evidence” really means “insufficient funding.” When a promising molecule has no trial, the thing usually missing is a sponsor.

And it’s circular. The same regulatory system that says these peptides are “not well characterized” is a big part of why they’re not well characterized, because characterization costs money and there’s no exclusivity to earn it back against. The compounding pharmacies that sell the stuff can’t fund the trials either. They’d be paying to prove a molecule the pharmacy down the road also gets to sell.

The new policy fits that pattern. HHS’s reasons for letting BPC-157 through are documented historical use, “multiple human studies,” and a new lot-specific certificate of analysis from an FDA-registered facility (HHS policy, Appendix B). There’s no new trial in that list, because nobody ran one.

To be fair to the other side, this isn’t a conspiracy. No sponsor also means no curator. When one lab cares and nobody else has funding, you get one lab’s worth of research. That’s thin replication, and you should treat it accordingly.

Which is why human experience has to count for something

A study of 40 rats is not obviously stronger evidence than 400 logged human experiences. It’s weak in a different direction. Rats don’t lift, don’t sleep terribly, and don’t have your 47-year-old tendon. A trial tells you about the average of a population, and you’re one person.

So here’s how to tell a real self-experiment from vibes.

What makes an n=1 worth reading: a structured log with the date, what you took, the timing, and a scored symptom, not “felt better.” One variable at a time. A washout and re-challenge, which kills most placebo explanations. An objective endpoint, like a scan, a range of motion in degrees, or a lab value. A stable baseline, so the peptide doesn’t get credit for healing you were doing anyway.

How it fools you: people who post are people who got results. Injuries heal on their own. Expectation is real and large. And you probably also started sleeping more and eating better the same week.

Where the good material lives: peptide forums and clinic outcome reports. The good logs read like lab notebooks. The bad ones read like testimonials.

This matters because for most of these compounds, real-world logs are the entire human evidence base. Treating them as rumor while treating a 12-rat study as proof is a category error.

One that might work, and one that didn’t

BPC-157 is the maybe. Decades of rodent data showing faster healing of tendon, ligament and gut tissue. Thousands of people logging it working. And the human record, right now, is three small studies totaling about 30 people: a two-person IV safety pilot (Lee & Burgess, 2025), a look back at 16 people who got knee injections, and 12 people treated for interstitial cystitis. An October 2026 systematic review rated all three poor quality, with very low certainty (Acta Orthopaedica Belgica).

The first randomized, placebo-controlled trial, in hamstring strains, has been recruiting since February. Its main results aren’t due until 2027, and the study runs into 2028 (NCT07437547). A U.S. trial after rotator cuff surgery hasn’t started yet (NCT07803250). The 2015 safety trial still never reported (NCT02637284). Half the gym swears by it, and nobody has proven it yet. A government policy doesn’t change that.

AOD-9604 is the cautionary tale. A growth hormone fragment sold for fat loss. It actually got a real trial, over 500 people for 24 weeks, and it failed. Weight loss wasn’t meaningfully better than placebo, and development was abandoned in 2007 (company announcement; Stier et al.). People still sell it as a fat burner, because people still buy it. It isn’t one of the six in the new policy.

Two different molecules, same lesson: a trial can kill a molecule, and the lack of a trial can keep a live one in limbo forever.

Meanwhile, where there’s money, there’s evidence

This is the contrast that proves the whole point. Semaglutide and tirzepatide are the two peptides we actually know about. We know how much weight people lose: about 15% of body weight on semaglutide over 68 weeks (STEP 1, NEJM 2021), and roughly 15 to 21% on tirzepatide (SURMOUNT-1, NEJM 2022). We know the side effects. We know semaglutide cut heart attacks, strokes and cardiovascular deaths by about 20% in people with existing heart disease (SELECT, NEJM 2023).

We know all that because there was a billion-dollar reason to study them. Nobody had that reason for BPC-157.

This section is built from the Federal Register notice and the HHS policy itself, not from headlines or seller emails. I’m not a lawyer, and this isn’t legal advice.

What HHS did

On Oct 28, 2026, HHS filed a notice for an “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances.” It was published in the Federal Register on Oct 30 (91 FR 68526, document 2026-22192), signed by HHS Secretary Robert F. Kennedy Jr. Before that, the White House budget office reviewed it from Oct 14 to Oct 27 and cleared it “consistent with change” (reginfo.gov).

In plain English: HHS says it won’t take enforcement action against a state-licensed pharmacy, a federal facility or a licensed physician that compounds one of six peptides for an individual patient, as long as all ten of its conditions are met. “Enforcement discretion” means the government is choosing not to enforce a rule, for now. Nobody approved anything.

The notice itself calls this a “draft” policy and an “interim policy,” and says it is “not binding on HHS or the public.” The HHS policy document reads as a current enforcement position. That’s why I describe it as in effect as an interim policy, even though the notice calls it a draft.

The six, and how each may be given

Peptide Covered form Allowed routes
BPC-157 acetate under the skin, into muscle, by mouth, on the skin
TB-500 acetate under the skin or into muscle
MOTS-c acetate under the skin or into muscle
Epitalon acetate under the skin or into muscle, in intermittent courses
Semax free base nasal spray only
KPV acetate on the skin or by mouth only

Source: HHS policy, Appendix B.

One catch on the pills. HHS says getting peptides absorbed by mouth is “inherently difficult,” so a pharmacy making an oral version has to keep documentation that the specific formulation is actually absorbed in humans. Most oral peptides aren’t.

The conditions, in plain words

  • A prescription for you specifically. Each product has to be made on a valid, patient-specific prescription.
  • One peptide per product. Condition 7 says the compounded product can contain only a single active ingredient from the list, so blends such as BPC-157 with TB-500 in one product aren’t covered.
  • Tested raw material from a registered maker. The original manufacturer has to be registered with FDA and following good manufacturing practices, and every lot needs a certificate of analysis covering identity, purity and potency, plus contaminants like endotoxins, heavy metals and microbes.
  • Problems get reported. Pharmacies report serious side effects and quality problems to FDA’s MedWatch program and to the states.
  • A plain label. It has to say, “This is a compounded drug product. Not for resale.”
  • Syringes only. The only delivery device allowed is an FDA 510(k)-cleared syringe. Pens and fancier devices don’t qualify.
  • Everything else in the law still applies, including clean, sanitary conditions.

What it does NOT do

  • It isn’t FDA approval. HHS says so itself: compounded drugs “are not FDA-approved” (Federal Register).
  • It doesn’t put them on the official list. Getting onto FDA’s 503A bulks list still takes rulemaking with public comment. The policy only lasts “until a peptide bulk drug substance is addressed in a final rule.”
  • It doesn’t cover “research use only” vials. The policy only covers licensed pharmacies, federal facilities and physicians using registered, tested raw material for a named patient. The online RUO market sits outside all of that, and the August warning letters still stand.
  • It doesn’t cover big-batch outsourcing facilities. The text only addresses 503A pharmacies, federal facilities and physicians. Law-firm analyses from Fox Rothschild and BakerHostetler read that as leaving out 503B outsourcing facilities. That’s their reading, not words HHS wrote.
  • It doesn’t cover other peptides, blends, or other forms. CJC-1295, ipamorelin, GHK-Cu, AOD-9604 and DSIP aren’t on the list. Neither is a different salt form of one of the six.
  • It isn’t permanent. HHS calls it interim and says it may revisit the policy, in whole or in part, if a safety signal or quality problem shows up.
  • It doesn’t change sports rules. WADA bans BPC-157 at all times under S0 and TB-500 under S2, and the 2027 list names “peptides” in general under S0 (USADA). If you’re tested, you’re responsible for what’s in your body, prescription or not.
  • It doesn’t override your state. State pharmacy boards still regulate pharmacies, so ask the pharmacy whether your state allows it.

How we got here

FDA put BPC-157 and the other five in its “Category 2” safety-concern group in September 2023 and took them out on April 22, 2026 (FDA). HHS’s own appendix says neither move changed their legal status for compounding. In July, FDA’s Pharmacy Compounding Advisory Committee voted in favor of these peptides, 8 to 6 for BPC-157 (FDA meeting page; AJMC). FDA’s drug staff recommended against listing all six, which HHS’s appendix confirms.

If a clinic tells you the FDA “approved” it, they’re rounding up. If a seller tells you their research vial is legal now, they’re making it up.

The comment period is closed

Public comments on regulations.gov, docket HHS-OASH-2026-0496, closed Nov 13, 2026 at 11:59 PM ET (10:59 PM CT). HHS received 289 of them. It hasn’t issued a final policy, and it hasn’t said what comes next or when. Until it does, the Oct 30 draft policy still stands.

Nobody is testing your vial

Here’s the part I feel strongest about. Sellers love to post a “Certificate of Analysis” showing 99% purity. A COA is a PDF, and PDFs get faked, copied across batches, or borrowed from another company.

In 2026, independent labs started putting numbers on it. One reported that roughly a third of the samples it tested failed basic quality checks (The Guardian, April 2026). One small independent test of 10 vials reported a fake “semaglutide” that was a different compound entirely, plus budget vials with endotoxin and heavy-metal contamination (The Peptide List, 2026).

A pill bottle of vitamin D with a fake COA is a disappointment. A vial with endotoxin is a night in the ER.

The new policy does help here, for pharmacy product. It requires a lot-specific COA from an FDA-registered manufacturer, with tests for endotoxin, microbes and heavy metals spelled out. If you’re going to use one of these at all, that’s the strongest practical reason to go through a pharmacy instead of a research vial. It doesn’t make every COA you see online real.

Outside the pharmacy route, the only COA worth anything comes from an independent lab testing the exact batch in your hand. Even then, purity and sterility are two different tests, and most COAs don’t cover the second one. I don’t sell peptides or anything else on this site, and here’s why.

The risks, condensed

Most of these are shots under the skin done in a kitchen. Infection, abscess, contamination, dosing errors from mixing powder at home. None of it theoretical.

And the one worth thinking about at 40-plus: several of these work by turning up growth signals like new blood vessels and IGF-1. Tumors use those same signals. Higher IGF-1 is linked in large studies to a handful of cancers, including breast, prostate and colorectal (UK Biobank, Cancer Epidemiol Biomarkers Prev 2020). Nobody’s shown these peptides cause cancer. Nobody’s shown they don’t. After 40, you’re more likely to be carrying something small and undiagnosed.

Legal to compound doesn’t mean shown to be safe. FDA’s own drug staff recommended against listing all six. HHS’s appendix answers that for some of them by calling the staff’s safety concerns “mechanistic rather than observed” or “inferential rather than observed” (HHS policy, Appendix B). That’s a fair point.

“No evidence of harm” means “nobody studied it long enough.” That’s an unknown, and I wouldn’t treat it as a reassurance.

Your doctor

My doctor now, whom I found long after that shoulder prescription, is an internist and a naturopath with a food-first approach, and I’ve found that being upfront with a doctor works better than hiding things.

Tell them everything. They can’t watch labs for something they don’t know about. Name the goal: injury, weight, sleep, energy. There may be a proven option that deserves a look first, and for recovery that often starts with sleep. Ask for baseline labs if it’s growth-hormone related. And don’t expect a lecture or give one. A good doctor tells you the risks and respects that it’s your body.

The new policy changes one thing about this conversation. The legal route now runs through a prescription, so your doctor is part of it whether you planned on that or not. If you go that way, here’s what I’d ask:

  • Which state-licensed (503A) pharmacy would make it?
  • Can the pharmacy show me the certificate of analysis for the actual lot?
  • What route, and for how long?
  • What labs should we check before and during?
  • How do I report a side effect, to you and to FDA’s MedWatch?

Bottom line

The approved peptides have real evidence and known risks. Doctor and pharmacy.

Collagen is food. Low-risk, modestly helpful.

BPC-157 and five others can now be compounded by a licensed pharmacy with a prescription, under an interim HHS policy that could change. That’s a change in who can legally make them. The evidence that they work is right where it was last month.

Everything else rests on animal data, a couple of thin human trials, and a big pile of real-world logs, sold by a market where a third of the vials fail basic checks.

Some of these will turn out to be useful. Right now we don’t know, and the reason we don’t know is that proving it wouldn’t make anyone rich enough to bother.

“Insufficient evidence” is a funding statement wearing a lab coat.

Before any of this, the boring basics have real trials behind them: lifting, protein and sleep. Make your own call. Just make it with your eyes open, your doctor in the loop, and a real lab report in your hand instead of a seller’s PDF.

Frequently asked questions

Did the FDA approve BPC-157?

No. BPC-157 isn’t FDA-approved for any use, and it isn’t on FDA’s 503A bulks list. The October 2026 HHS policy only says HHS won’t act against certain pharmacy compounding while FDA decides, through rulemaking, whether to list it. HHS’s own notice says compounded drugs are not FDA-approved and that FDA doesn’t review their safety, effectiveness or quality before they’re sold.

Can I get BPC-157 from a compounding pharmacy now?

Under the interim HHS policy, yes, with conditions. You need a prescription written for you. A state-licensed 503A pharmacy, federal facility or licensed physician has to make it as BPC-157 acetate, with no other peptide in the product, from raw material made in an FDA-registered facility with a lot-specific certificate of analysis. State pharmacy rules still apply, so ask the pharmacy.

No. The policy only covers products compounded by licensed pharmacies, federal facilities or physicians, from registered, tested raw material, for a named patient. HHS says the point is to steer people away from research-use-only peptides from foreign suppliers. Vials sold online “for research only” are still unapproved drugs, and FDA sent warning letters to five such sellers in August 2026.

Can I get a BPC-157 and TB-500 blend?

Not under this policy. Condition 7 of the policy says each compounded product can contain only one active ingredient from the list. HHS says single-ingredient products make it easier to tell which substance caused a side effect or a result. So the “Wolverine stack” in one vial isn’t covered, even from a licensed pharmacy with a prescription.

Is BPC-157 still banned in sports?

Yes. A prescription doesn’t change anti-doping rules. USADA’s 2027 advisory lists BPC-157 as prohibited at all times under WADA’s S0 class and TB-500 under S2, and the 2027 list names “peptides” in general under S0. If you’re a tested athlete, including masters competitors, check Global DRO or your federation before using anything.

How long does this last, and can it be reversed?

It’s interim. HHS says it applies until FDA addresses each peptide in a final rule on the 503A bulks list. HHS also says it may revisit the policy, in whole or in part, if a safety signal or quality problem shows up, and the notice says it isn’t binding. It could change at any time, or end.

Can I still comment on the policy?

No. The comment period closed Nov 13, 2026 at 11:59 PM Eastern (10:59 PM Central), and HHS received 289 comments on docket HHS-OASH-2026-0496. No final policy has been issued, and HHS hasn’t said what comes next or when, so the Oct 30 draft policy still stands for now. The docket is still on regulations.gov if you want to follow it.

Sources

  1. 1.Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (91 FR 68526, Oct 30, 2026). Federal Register. (PDF)
  2. 2.HHS Enforcement Discretion Policy, with Appendices A and B. U.S. Department of Health and Human Services.
  3. 3.Docket HHS-OASH-2026-0496. Regulations.gov.
  4. 4.Interim Access Policy for Compounding Using Certain Peptides, review concluded Oct 27, 2026. OMB, reginfo.gov.
  5. 5.July 23–24, 2026 meeting of the Pharmacy Compounding Advisory Committee. FDA.
  6. 6.FDA panel backs 6 peptides for compounding. AJMC.
  7. 7.FDA, Category 2 list. FDA.
  8. 8.FDA warning letter, Peptide Partners LLC (Aug 24, 2026). FDA.
  9. 9.Athlete advisory: 2027 Prohibited List. USADA.
  10. 10.Analysis: HHS moves to pull peptides out of the research-use-only market and into pharmacies. Fox Rothschild (law-firm analysis).
  11. 11.Analysis: HHS issues enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances. BakerHostetler (law-firm analysis).
  12. 12.RFK Jr., peptides and the FDA (July 2026). Fortune.
  13. 13.JAMA Internal Medicine, 2018. JAMA Internal Medicine.
  14. 14.Sikirić et al., J Physiol Paris, 1993. Journal of Physiology (Paris) via PubMed.
  15. 15.Lee & Burgess, 2025. PubMed.
  16. 16.Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review (Oct 8, 2026). Acta Orthopaedica Belgica.
  17. 17.BPC-157 hamstring strain trial NCT07437547. ClinicalTrials.gov.
  18. 18.BPC-157 rotator cuff repair trial NCT07803250. ClinicalTrials.gov.
  19. 19.BPC-157 trial registration NCT02637284. ClinicalTrials.gov.
  20. 20.AOD-9604 development stopped (company announcement, 2007). ASX announcement via Market Index.
  21. 21.Stier et al., AOD-9604 trial. Journal of Endocrinology and Metabolism.
  22. 22.STEP 1, NEJM 2021. New England Journal of Medicine via PubMed.
  23. 23.SURMOUNT-1, NEJM 2022. New England Journal of Medicine via PubMed.
  24. 24.SELECT, NEJM 2023. New England Journal of Medicine via PubMed.
  25. 25.The Guardian, April 2026. The Guardian.
  26. 26.The Peptide List, 2026. The Peptide List.
  27. 27.UK Biobank, Cancer Epidemiol Biomarkers Prev 2020. Cancer Epidemiology, Biomarkers & Prevention via PMC.

Links checked November 14, 2026. Figures are quoted from the sources above; associations in observational studies don't prove cause and effect.

Keep reading

The Still Well letter

Plain-English notes on strength, energy, recovery, and staying capable after 40. No hype, no spam. The list launches soon — until then, reach us at [email protected].

Signup isn't open yet. We'll turn this on when the email list is ready.